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Abstract
Background: Multiple sclerosis (MS) is an immune-mediated disease that damages myelin in the central nervous
system (CNS). We investigated the profile of CCN3, a known regulator of immune function and a potential mediator
of myelin regeneration, in multiple sclerosis in the context of disease state and disease-modifying treatment.
Methods: CCN3 expression was analysed in plasma, immune cells, CSF and brain tissue of MS patient groups and
control subjects by ELISA, western blot, qPCR, histology and in situ hybridization.
Results: Plasma CCN3 levels were comparable between collective MS cohorts and controls but were significantly
higher in progressive versus relapsing-remitting MS and between patients on interferon-β versus natalizumab.
Higher body mass index was associated with higher CCN3 levels in controls as reported previously, but this
correlation was absent in MS patients. A significant positive correlation was found between CCN3 levels in matched
plasma and CSF of MS patients which was absent in a comparator group of idiopathic intracranial hypertension
patients. PBMCs and CD4+ T cells significantly upregulated CCN3 mRNA in MS patients versus controls. In the CNS,
CCN3 was detected in neurons, astrocytes and blood vessels. Although overall levels of area immunoreactivity were
comparable between non-affected, demyelinated and remyelinated tissue, the profile of expression varied
dramatically.
Conclusions: This investigation provides the first comprehensive profile of CCN3 expression in MS and provides
rationale to determine if CCN3 contributes to neuroimmunological functions in the CNS.
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Background
Multiple sclerosis (MS) is an inflammatory, neurodegen-
erative disease characterised by central demyelinating
events disseminated in time and space. Efficient myelin
regeneration (remyelination) declines with age and re-
mains an unmet clinical need that has the potential to
be neuroprotective and functionally restorative for pa-
tients with all types of MS. With a renewed focus on
therapies for progressive MS and regenerative strategies
that may prevent further disability, new compounds are
being identified to enhance the regeneration of myelin
by oligodendrocytes.
Although most MS treatments block either peripheral
immune cell function or access to the CNS, immune
cells are increasingly recognised as key players in modu-
lating tissue regeneration. Indeed, depletion of T cells or
specific subsets such as regulatory T cells (Treg) im-
pedes myelin regeneration in vivo [1, 2]. A protein se-
creted by T cells called cellular communication network
factor 3 (CCN3) was found to increase oligodendrocyte
differentiation in experimental models in vitro and
ex vivo [1]. CCN3 was previously known as nephroblas-
toma overexpressed or NOV [3]. It is a matricellular
protein of the CCN family (CCN1-6) [4]. These proteins
are dynamically expressed in development and injury
settings, and have cell regulatory functions rather than
structural roles [5–7]. CCN proteins comprise 4 domains
which have homology to insulin-like growth factor bind-
ing proteins (IGFBPs), von Willebrand factor type C re-
peat (VWC), thrombospondin type I repeat (TSP1) and a
carboxy-terminal domain (CT) containing a cystine knot.
As such, CCN proteins can modulate the binding affinity
or bioavailability of various ligands as well as directly
interact with cell surface receptors [8–10]. In the case of
CCN3, this includes Notch, integrins αvβ3 and α5β1, hep-
arin sulphate proteoglycans (HSPGs) and S100A4 calcium
binding protein [11–14]. CCN3 has been ascribed mul-
tiple signalling roles that can influence proliferation, dif-
ferentiation and inflammatory processes in a cell-specific
and context-dependent manner including in Treg-
mediated oligodendrocyte differentiation [15, 16]. CCN3
plays various roles in the immune system. It is essential
for normal functioning of haematopoietic stem cells
(HSCs) [17, 18], is an adipokine linked to obesity-induced
insulin resistance [19, 20] and is a regulator of cytokine
expression in both the periphery and CNS [19, 21, 22].
The CCN3 promoter is a direct target of the FoxO1 tran-
scription factor, which is essential for CD4+ T cell fitness
[23]. Indeed, Treg-specific deletion of FoxO1 results in le-
thal inflammation due to loss of tolerance [24], and its ex-
pression is reduced in CD4+ and CD8+ T cells in MS [25].
Given the importance of CD8+ and CD4+ T cells, in MS,
it is pertinent to explore whether CCN3 expression is al-
tered in MS.
We and others have reported that CCN3 is extensively
expressed in the murine CNS, primarily by neurons in the
cerebral cortex, hippocampus, amygdala, suprachiasmatic
nuclei, anterior olfactory nuclei and spinal cord grey matter
[26–32]. Despite this, much of its functional significance in
the CNS is still to be explored. In humans, CCN3 has so far
been detected in developing brain tissue [33–35] and cere-
brospinal fluid (CSF) [36, 37]. It is reported to negatively
regulate granule precursor neuron proliferation, inhibit
axonal callosal projections during development and
upregulate CXCL1 and CCL2 in astrocytes in murine brain
[21, 29, 38]. CCN3 from regulatory T cells (Treg) enhanced
oligodendrocyte differentiation in mixed glial cultures and
is upregulated in GFAP+ cells and oligodendroglial cells of
remyelinating lesions, but CCN3 was not essential for
(re)myelination as demonstrated in CCN3−/− mice [1, 32].
Further investigation is necessary to determine whether this
modulatory protein with distinct expression in CNS and
immune compartments has potential therapeutic value in
demyelinating diseases such as MS. To this end, we con-
ducted extensive profiling of CCN3 expression in healthy
and MS disease states to answer whether CCN3 is dysregu-
lated in MS and determine whether there is rationale for
CCN3-mediated regenerative mechanisms as a therapeutic
target for neurological disease.
Methods
Participants
This study was approved by the Yorkshire & the Hum-
ber - Leeds West Research Ethics Committee (15/YH/
1071) and the institutional ethics committee of Queen’s
University Belfast. Written informed consent was ob-
tained from all participants in the study according to the
Declaration of Helsinki. Blood samples were collected
with informed consent from healthy volunteers and from
patients attending the MS clinic at Belfast City Hospital
(Belfast Health and Social Care Trust). Patients diag-
nosed with MS according to the 2010 McDonald criteria
and receiving natalizumab (Nat), interferon-β (IFN) or
no treatment for relapsing-remitting MS (RRMS) or di-
agnosed as secondary or primary progressive (PrMS)
were included in the study. Donors were excluded if
under 18 years old, pregnant or had other inflammatory
comorbidities as determined by questionnaire and/or re-
view of clinical notes.
Matched plasma samples from MS patients in relapse
or in remitting phases of disease were provided by Dr.
Bruno Gran, University of Nottingham. Matched sam-
ples of plasma and CSF collected during routine neuro-
logic workups between 2012 and 2017 from age- and
sex-matched cohorts with RRMS or idiopathic intracra-
nial hypertension (IIH) were obtained from the Welsh
Neuroscience Research Tissue Bank, Cardiff University
(Rec Ref. 14/WA/0073). Patients with obesity (BMI >
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30) were recruited from the Weight Management Ser-
vice at St Columcille Hospital led by Prof. Donal O'Shea.
Healthy bodyweight controls (BMI ≤ 25) were recruited
from St. Vincent’s University Hospital.
Demographic data of the cohorts included in this
study are presented in Supplementary Tables 1–5.
Blood sampling, collection and storage
Blood samples were processed fresh and within 2 h.
Blood was collected into EDTA-containing tubes and
centrifuged at room temperature at 400 g for 10 min.
The upper phase was transferred to a fresh tube and
centrifuged at 2000g for 10 min. Plasma was then ali-
quoted and stored at − 80 °C.
Gene expression in PBMCs, CD4+ T cells and CD4− cells
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole blood in 2% foetal bovine serum in
PBS using Ficoll-Paque (GE Healthcare, 17-1440-02) in
Sepmate tubes (StemCell Technologies). CD4+ T cells
were then isolated using StemCell Technologies Robo-
Sep™ Human CD4+ T Cell Isolation Kit (Cat. No.
#17952RF) according to the manufacturer’s instructions.
RNA was extracted using Trizol reagent (Thermo
Fisher) and assessed for purity and concentration by
Nanodrop spectrophotometry. Samples were treated
with DNase I (Invitrogen) before reverse transcription
with Superscript IV (Invitrogen) as described previously
[1]. qPCR was performed using Taqman Universal PCR
Mastermix (Thermo Fisher) and probes for CCN3
(Thermo Fisher; Hs00159631_m1) and SDHA
(Hs00188166_m1) as a reference gene. Gene expression
changes are reported as fold changes relative to healthy
controls using the 2−ddCt method.
Measurement of CCN3 by ELISA
CCN3 levels in biological fluids and T cell culture super-
natants were assessed by ELISA according to the manu-
facturer’s instructions (DY1640 DuoSet kit, R&D
Systems). Standard curves were generated using four-
parameter logistic curve-fit.
Immunoblotting of CCN3
Plasma, CSF or h295-R cell-conditioned media were
enriched for CCN3 using heparin-sepharose beads (GE
Healthcare, #17-0998-01) as previously described [35].
In short, up to 4 ml (equivalent to at least 20 ng of
CCN3) was added to 20 μl 50% heparin-sepharose slurry
and incubated on a rotator at 4 °C overnight. In total,
25 μl of PBS-washed CCN3-bound heparin-sepharose
beads and 5 μl of 6× reducing loading dye were boiled
for 10 min prior to loading on a reducing 15% SDS-
PAGE. Following transfer onto PVDF membrane (Milli-
pore) and blocking (3% BSA in PBS/1% Tween) for 1 h
at room temperature, protein was probed using poly-
clonal goat anti-human CCN3 antibody (0.1 mg/ml; cat.
no. AF1640, R&D Systems) overnight at 4 °C and sec-
ondary rabbit anti-goat HRP (1:2000; #61-1620) for 1.5 h
at room temperature. Bands were detected by chemilu-
minescence using Pierce™ ECL Western Blotting Sub-
strate (Thermo Fisher, #32106) and imaged using a G:
BOX detection system (Syngene).
MS lesion characterisation and analysis
Immunohistochemistry was carried out on clinically and
neuropathologically validated paraffin wax-embedded
tissue from the UK Multiple Sclerosis brain bank at Im-
perial College London (research ethics approval 08/
MRE09/31+5). All cases of MS and non-neurological
controls had a death to preservation time of < 24 h, with
the exception of control 03 (Ctrl03; death to preserva-
tion time of 36 h; Supplementary table 5). One or two
pathological blocks containing cortical grey and subcor-
tical white matter (superior frontal or cingulate cortex)
were selected per case following tissue characterisation.
Tissue sections were stained with Luxol-Fast Blue (LFB)
and immunohistochemically stained with anti-
proteolipid protein (PLP) and anti-CD68 to characterise
areas of inflammatory demyelination or remyelination in
the grey and white matter. White matter lesions were
defined as active (demyelinated lesion with abundant
CD68+ microglia/macrophages throughout the lesion
and the presence of myelin (PLP+) degradation prod-
ucts); chronic active (abundant CD68+ microglia/macro-
phages restricted to the lesion edge and the presence of
myelin degradation products) or chronic inactive (small
numbers of mostly ramified CD68+ microglia at the
well-defined lesion edge). Fully remyelinated white mat-
ter lesions were classified as shadow plaques based on
the ‘normally appearing’ PLP profile and classic LFB
‘shadow’ appearance. Grey matter lesions were charac-
terised based on their location, and subpial cortical grey
matter lesions (clear ribbons of subpial cortical demye-
lination extending partly through the depth of the cor-
tex), being the most common cortical grey matter lesion
type in acute and progressive MS [39], were selected for
analysis. Putative areas of cortical grey matter remyelina-
tion were defined based on a reduced density of PLP+
myelin sheaths and the presence of numerous PLP+
oligodendrocyte cell bodies per microscopic field of view
[40].
Immunostaining
Briefly, following dewaxing in xylene and rehydration
through a graded series of ethanol, slides from MS and
control cases were heated in a 0.05% solution of citraco-
nic anhydride (Sigma; for immunohistochemistry) or so-
dium citrate (pH 6) for subsequent immunofluorescence
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cytochemistry. Endogenous peroxidases were quenched
with a 0.6% hydrogen peroxide before a serum block.
Slides were then incubated with primary antibody over-
night (Table 1). Slides were washed, and relevant
species-specific biotinylated secondary antibody (raised
in horse or goat; Vector Laboratories) was applied. For
immunohistochemistry, antibody binding was visualised
with the avidin-biotin-complex (ABC) peroxidase-linked
reporter system, with 3,3′-diaminobenzidine (DAB;
Immpact DAB; Vector) as chromogen. Tissue sections
were counterstained with Gill’s haematoxylin No. 2
(GHS232; Sigma) and mounted with DPX. Please note
that for quantitative analysis of CCN3+ immunoreactiv-
ity all slides were stained in the same experimental run.
For dual antibody immunofluorescence, bound primary
antibody 1 (anti-human nuclear antigen (HuC)) was de-
tected with an Alexa-488 conjugated anti-mouse second-
ary and the sequentially added primary antibody 2 (anti-
CCN3) detected with an Alexa-546 anti-goat secondary.
Slides for immunofluorescence were then quenched with
0.05% Sudan Black B to reduce autofluorescence before
mounting in 12.5% mowiol/glycerol with DABCO. Nega-
tive controls were included, and in all instances, the rele-
vant IgG control, or the absence of the secondary
detection antibody, yielded no signal.
In situ hybridisation
In situ hybridisation (ISH) was performed using a 5
fluorescein (FAM)-labelled 22mer antisense oligonucleo-
tide containing locked nucleic acid (LNA) and 2-O-
methyl (2-O-Me)-RNA moieties in a 1:2 ratio (Eurogen-
tec, Southampton, UK). Probe design was as follows:
antisense CCN3 (NM_002514) FAM–CauCucAcaUu-
gAcgGuuCcuA and sense FAM–TagGaaCcgTcaAtgTga-
GatG (capitals indicate LNA and lowercase 2-O-Me-
RNA). Following dewaxing, rehydration and antigen re-
trieval, sections were pre-hybridised in hybridization mix
[41] before probe hybridization (30 min) in the same so-
lution. Sections were then washed in decreasing concen-
trations of saline-sodium citrate buffer, washed in PBS,
incubated with a peroxidase conjugated goat anti-FAM
(Vector Labs) and visualised with DAB. Sections were
counterstained with haematoxylin before dehydrating,
clearing and mounting with DPX.
Image acquisition and QuPath analysis
Immunohistochemically stained tissue sections for PLP,
CD68 and CCN3 were digitised by whole slide-scanning
using a Leica SCF400F scanner and handled using
QuPath [42]. Areas of chronic active white matter de-
myelination and subpial cortical grey matter lesions,
alongside areas of remyelinated white and grey matter,
were first traced using the annotation tool on the PLP-
stained slide for each section. The annotation was then
transferred to the same location on the sequential
CCN3-stained slide from the same case and the area
fraction (% CCN3+ immunoreactivity) of the entire le-
sion or normal-appearing region of interest calculated.
Statistical analyses
Analyses were performed with Microsoft Excel and
GraphPad Prism. Normality of datasets was determined
using the D’Agostino and Pearson test. Parametric data-
sets were tested for statistical significance using two
tailed t-tests to compare two groups or one-way analysis
of variance (ANOVA) with Tukey’s post hoc test for
more than two groups. Mann-Whitney U tests or Krus-
kal Wallis tests with Dunn’s post hoc test were used for
non-parametric data as appropriate. Comparisons be-
tween matched samples during relapse or remittance, or
pre- and post-liraglutide were tested with Wilcoxon
matched-pairs signed rank test. Correlation analyses
were performed using the Pearson test for parametric
data or the Spearman test for non-parametric data. Data
are presented as means and standard error of the mean
(SEM) unless otherwise stated. * = p < 0.05. ** = p <
0.01, *** = p < 0.001.
Data availability
Anonymised datasets used and/or analysed during the
current study are available from the corresponding au-
thor on reasonable request.
Results
Plasma CCN3 levels are altered by MS disease phase and
treatment
To assess whether CCN3 levels were altered in MS,
plasma samples from patients with MS or age- and sex-
matched healthy controls (HC) were analysed by ELISA.
Mean CCN3 plasma concentration did not differ
Table 1 Antibodies used for immunohistochemistry
Antibody (anti-) Target Source Type/clone Dilution
PLP Proteolipid protein myelin Abd Serotec, USA mAb/plpc1 1:2000
CD68 Sialomucin, microglia and macrophages DAKO, Denmark mAb/KP1 1:400
CCN3 Human CCN3 protein R&D Systems pAb (AF1640) 1:200
HuC/D Human HuC/HuD neuronal protein Thermo Fisher Scientific mAb/16A11 1:2000
Primary antibodies used in this study
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between groups (MS; 8.58 ± 4.45 ng/ml; HC 10.61 ±
8.29 ng/ml, Fig. 1a), but significantly higher CCN3 levels
were observed in patients with progressive MS (PrMS)
versus RRMS (PrMS; 12.14 ± 5.86 ng/ml; RRMS 7.89 ±
3.87 ng/ml, Fig. 1b). A significant effect of treatment was
detected in RRMS patients. Post hoc tests detected sig-
nificantly elevated levels of CCN3 in patients on
interferon-β versus those on natalizumab (IFN-β; 10.52
± 5.66 ng/ml, natalizumab; 6.49 ± 1.87 ng/ml, Fig. 1c).
Matched samples were analysed from MS patients dur-
ing relapse and remitting phases of disease, but no dif-
ference in plasma CCN3 was detected (Fig. 1d). To
concentrate samples for detection by western blot,
plasma samples were incubated on heparin-sepharose
beads to which CCN3 binds through the C-terminal do-
main. Two major CCN3 isoforms were detected in
plasma of both MS patients and healthy controls at ap-
proximately 54 kDa and 25 kDa, likely representing full-
length CCN3 and the amino-truncated isoform detected
in the control cell culture-conditioned medium of h295-
R cells expressing CCN3 [43] (Fig. 1e).
Obesity-associated changes in plasma CCN3 levels are
evident in MS
Increasing body mass index (BMI) was reported to
strongly correlate with increasing plasma CCN3 levels
[44]. To validate this finding, serum CCN3 concentra-
tions were analysed from obese patients and healthy
bodyweight (‘lean’) controls who did not have MS. This
revealed significantly raised levels of CCN3 in groups in
which BMI differences ranged from 25 kg/m2 between
lean and obese cohorts, to just 1–5 kg/m2 in matched
Fig. 1 Plasma CCN3 levels are altered by MS disease phase and treatment. Plasma CCN3 levels are compared in healthy controls and MS (a),
controls and MS disease phase (b), RRMS treatment groups (c) and matched samples from RRMS patients during relapse or remittance (d).
Detection of plasma-derived CCN3 by western blot (e). Abbreviations: HC, healthy control; MS, multiple sclerosis; RRMS, relapsing-remitting MS;
Prog MS, progressive MS; TN, treatment-naïve; Nat, natalizumab treatment; IFN, interferon-β treatment; Ctl, h295-R-conditioned medium as
positive control
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samples from patients pre- and post-treatment with the
glucagon-like peptide (GLP)-1 agonist, liraglutide (Fig. 2a,
b). This mirrored changes observed in leptin, another adi-
pokine, in this cohort (Fig. 2c). Linear regression analysis
confirmed a significant relationship between BMI and
CCN3 plasma levels in age- and sex-matched healthy con-
trols, but this relationship was absent in MS patients (Fig.
2d,e; HC; r2 = 0.427, slope = 1.294 ± 0.50, p = 0.029 MS; r2
= 0.018, slope = − 0.113 ± 0.17, p = 0.505). This effect was
most prominent in obese patients with MS (BMI > 30), and
this effect had no clear association to any treatment group
or progressive disease (Fig. 2e).
CCN3 mRNA is significantly upregulated in peripheral
immune cells in MS
CCN3 has previously been shown to be secreted by
polarised murine T cells in vitro [1]. While we occasion-
ally observed detectable CCN3 from human CD4+ T cell
culture-conditioned medium, it was not consistent
across donors or conditions and was very close to the
limit of detection (data not shown).
We asked whether regulation of CCN3 gene expres-
sion by immune cells is altered in MS. CCN3 mRNA ex-
pression was upregulated in PBMCs of MS versus
matched controls and in both CD4− and CD4+ immune
cells as determined by qPCR (Fig. 3a–c). While only one
third of samples from healthy controls had detectable ex-
pression of CCN3 mRNA in the CD4+ cell population,
87% of samples from MS patients had detectable expres-
sion (Fig. 3c). CCN3 expression was notable in all disease
and treatment groups tested. No correlation was observed
between CCN3 gene expression by peripheral immune
cells and plasma concentration (data not shown).
Significant correlation between plasma and CSF levels of
CCN3 in MS
Although CCN3 has previously been detected in human
CSF [36], the physiological concentration range and rela-
tionship to plasma levels had not been established. To ad-
dress whether these parameters change in MS, we analysed
matched plasma and CSF samples from RRMS patients who
had lumbar puncture performed for diagnosis. This was
compared to an age- and sex-matched cohort of patients
with idiopathic intracranial hypertension (IIH) who under-
went CSF shunting to relieve pressure on the brain. Identical
CCN3 isoforms were detected in plasma samples of IIH and
MS patients as had been detected in healthy controls (Fig.
1e, Fig. 4a). In contrast to plasma, only the higher molecular
weight isoform of CCN3 was detected in CSF and this was
consistent in both IIH and MS CSF samples (Fig. 4a).
CSF CCN3 levels were comparable between MS and
IIH groups and there was no difference between means
Fig. 2 Obesity-induced changes in plasma CCN3 levels are evident in MS. Plasma CCN3 levels in lean vs. obese cohorts (a), CCN3 levels (b) and
leptin levels (c) in plasma from obese patients before and after 12 weeks of GLP-1 agonist therapy. Corresponding plasma CCN3 levels and BMI in
healthy controls and MS (d) and stratified by disease phase and treatment (e). Abbreviations: HC, healthy control; MS, multiple sclerosis; RRMS,
relapsing-remitting MS; TN, treatment-naïve; Nat, natalizumab treatment; IFN, interferon-β treatment; MS-Pr, progressive MS
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of plasma or CSF levels in either group (Fig. 4b). Pearson
correlation analysis detected a significant correlation be-
tween increasing plasma and CSF concentration levels in
MS patients which was absent in IIH samples (Fig. 4b,
IIH: r2 = 0.125, ns; MS: r2 = 0.335, p < 0.01).
To determine whether CSF CCN3 levels were related to
neuropathological processes, we analysed expression
relative to CSF concentrations of neurofilament light
(NFL) chain protein, a marker of axonal degeneration. As
expected, MS CSF had higher NFL levels compared to IIH
CSF (Fig. 5a). The Spearman analysis identified a signifi-
cant correlation between increasing CCN3 and NFL con-
centration levels in CSF of IIH patients (Fig. 5b), but this
was not the case in MS samples (Fig. 5c, IIH: r = 0.532, p
Fig. 3 CCN3 is significantly upregulated in peripheral immune cells in MS. Fold change in CCN3 gene expression in PBMCs (a), CD4− (b) and
CD4+ (c) peripheral immune cells in MS relative to age- and sex-matched healthy controls. The percentages of samples with detectable
expression are indicated in red (left graphs, a–c). CCN3 mRNA expression levels in healthy controls and MS patients stratified by disease phase
and treatment (right graphs, a–c). Abbreviations: HC, healthy control; MS, multiple sclerosis; RRMS, relapsing-remitting MS; TN, treatment-naïve;
Nat, natalizumab treatment; IFN, interferon-β treatment; Prog MS, progressive MS
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< 0.05; MS: r = 0.326, ns). This suggests that more com-
plex, parallel processes lead to a non-linear relationship in
MS.
Area of CCN3 immunoreactivity is not significantly
different across MS lesions
Immunohistochemistry (IHC) revealed CCN3 protein
expression most consistently associated with adluminal
faces of arteries and vessels in both healthy control and
MS brain tissue (Fig. 6a,b). Large arteries and veins in
the subarachnoid space, connective tissue of the menin-
ges and pia, and epithelia of the choroid plexus displayed
anti-CCN3 immunoreactivity. Within the brain paren-
chyma, cells resembling neurons and macroglia were
anti-CCN3+ (Fig. 6c,d). Specific neuronal anti-CCN3 im-
munoreactivity was confirmed by dual
Fig. 4 Significant correlation between plasma and CSF levels of CCN3 in MS. Western blot of CCN3 in matched plasma and CSF of MS subtypes
and IIH controls (a). Relationship between plasma CCN3 and CSF CCN3 levels in IIH patients (black) and MS patients (red) (b). Abbreviations: CSF,
cerebrospinal fluid; IIH, idiopathic intracranial hypertension; MS, multiple sclerosis; +Ctl, h295R-conditioned medium
Fig. 5 Neurofilament levels and CCN3 levels correlate in CSF of IIH patients but not MS. Neurofilament light (NFL) levels in CSF of matched IIH
and MS donors (a). Relationship between CCN3 levels and NFL levels in CSF of IIH patients (b) and MS patients (c). Abbreviations: CSF,
cerebrospinal fluid; IIH, idiopathic intracranial hypertension; MS, multiple sclerosis; NFL, neurofilament light
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immunofluorescence with the neuron-lineage antigen
HuC/D (Fig. 6e) and by the detection of CCN3 tran-
script in large neuron-like cells with a pyramidal
morphology of the cerebral cortex (Fig. 6f). To under-
stand the relationship between relative CCN3+ immuno-
reactivity and MS pathology, we calculated the percent
Fig. 6 CCN3 immunostaining in normal and MS brain tissue. CCN3 is present in blood vessels, choroid epithelia and neuron-, and macroglia-like
cells of the CNS (black arrows, a–d). Co-labelled sections of MS grey matter with antibodies to the mature neuronal protein HuC/D (green) and
anti-CCN3 (red) demonstrates dual-labelling of CCN3 and HuC/D+ neurons (e). Detection of CCN3 transcripts by in situ hybridisation in MS grey
matter with a distinct neuronal morphology (f) and respective negative control (f, inset). Area of CCN3 immunoreactivity in MS brain tissue (n =
17 cases) (g). GM, normal-appearing grey matter; GM Lesion, demyelinated GM, GM remy, remyelinated GM; WM, normal-appearing white matter;
WM Lesion, demyelinated WM; WM remy, remyelinated WM
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area of specific anti-CCN3+ signal for normal-appearing,
demyelinated, and remyelinated white and grey matter,
respectively, from brain tissue blocks from 17 cases. The
extent of CCN3+ immunoreactivity was highly variable,
with, for example, cases of cortical grey matter remyeli-
nation presenting with > 15% of plaque comprising
CCN3+ structures. Nevertheless, the mean extent of
CCN3+ immunoreactivity was unchanged between any
of the MS regions of interest analysed (p > 0.9, Fig. 6g).
Discussion
We recently uncovered CCN3 as a key mediator of neu-
roimmune communication between T cells and glia in
the murine central nervous system [1]. Treg-derived
CCN3 promoted oligodendrocyte differentiation and
myelin production in murine in vitro and ex vivo
models. As this could have direct relevance for people
with demyelinating diseases such as MS, we wanted to
determine whether levels of CCN3 should be targeted
therapeutically. Evidence to support this approach would
be a deficit of CCN3 systemically (in plasma or CSF), lo-
cally (in lesion tissue) or potentially key cellular sources
(PBMCs, T cells). In this study, we observed no differ-
ence in CCN3 levels in plasma or CSF between people
with MS and controls indicating that there is no sys-
temic deficit to be addressed in MS. Furthermore, we
observed no difference in CCN3 levels between demyeli-
nated and remyelinated CNS lesions suggesting that
CCN3 production is not a limiting factor constraining
myelin repair. Despite comparable systemic levels,
CCN3 was significantly upregulated in PBMCs and T
cells of MS patients and almost absent in control sam-
ples, suggesting that cellular sources of CCN3 may vary
as a result of MS but overall levels are not altered. This
study shows that although our previous studies showed
that CCN3 can potentiate oligodendrocyte differenti-
ation, there is no paucity of CCN3 production that needs
to be addressed to boost myelin repair in MS. Indeed re-
cently published work by our group shows that CCN3-
deficient mice can efficiently regenerate myelin in mouse
models of remyelination [32]. While there are still no
remyelinating therapies available for MS, with clinical
trials only beginning in recent years, we believe that it is
important to the progress of the field to report the
follow-up of potential targets, even when, and indeed
particularly when, no overt differences are observed.
Though our study may be negative in this respect, it
points to other functions of this protein whose roles in
terms of immune function and regeneration are an ac-
tive area of research and which has been relatively un-
studied in the CNS or multiple sclerosis. Our data can
help provide clinical context and direction as this re-
search unfolds.
As in mice, we observed that activated human CD4+ T
cells secreted CCN3 in vitro. However, CCN3 levels
were near the limit of detection of the ELISA and would
not be sensitive enough to detect differences at that
range. Analysis of polarised T cells from mice suggests
that expression of CCN3 is subset specific (data not
shown). Gene expression analysis of CD4+ T cells and
PBMCs revealed stark differences between MS patients
and controls. In contrast to CCN3 expression in MS
samples, control samples had consistently low CCN3 ex-
pression in PBMCs and low positive detection rates in
CD4+ T cells. This mirrors CCN3 gene expression ana-
lysis of whole blood from healthy populations reported
elsewhere [45]. The functions of CCN3 in peripheral im-
mune cells are not well understood. CCN3 has been
identified as a critical regulator of human haematopoi-
etic stem cells from umbilical cord blood [17, 18].
Through increasing glycolytic enzymes and manipulating
stem cell state, soluble CCN3 dramatically increased the
number of serially transplantable cells. Preliminary work
indicated that CCN3 could stimulate mobilised adult
CD34+ cells in similar ways [17]. In MS patients treated
with natalizumab, persistent MRI and clinical disease ac-
tivity occurred in patients that lacked HSC mobilisation
post-treatment [46]. Understanding the role of CCN3 in
adult HSC and peripheral immune cells could reveal im-
portant insights for MS.
Plasma levels of CCN3 reflect many cellular sources
including adipose tissue and are known to correlate to
increasing BMI and obesity [20, 44]. No differences were
observed in plasma levels of CCN3 between MS and
HC. Further analysis confirmed a positive correlation of
CCN3 to BMI in the control cohort, but surprisingly,
there was no such correlation in the larger MS cohort.
Far from just an energy reservoir, adipose tissue exerts
systemic effects on endocrine and immune systems, pri-
marily mediated by adipokines. CCN3 is expressed by
adipocytes and is believed to contribute to obesity-
related inflammation and conditions including type 2
diabetes, sleep apnoea and obesity-induced cardiomyop-
athy [20, 44, 47, 48]. CCN3 is upregulated in adipose tis-
sue when mice are fed a high-fat diet whereas CCN3-
deficient mice gain less weight and have better glucose
tolerance and insulin sensitivity [19, 44]. Less inflamma-
tion was observed in the adipose tissue of CCN3-
deficient mice including significantly lower percentages
of CD4+ T cells. Our finding suggests that the strong as-
sociation between BMI and plasma CCN3 observed in
controls and in other studies diverges in MS patients
and this is most prominent in patients with high BMI.
Obesity, particularly at a young age, is an established risk
factor for MS [49–53], and differences in adipokine
regulation may prove important to disease pathogenesis
[54].
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Plasma levels of CCN3 were not altered during MS re-
lapse. In addition, plasma levels had no correlation to
EDSS, number of relapses in the past year or disease
duration (data not shown). This is in contrast to
rheumatoid arthritis, where higher serum CCN3 was as-
sociated with higher disease activity and inflammatory
markers [55]. Despite this, we observed that CCN3 was
raised in progressive MS compared to RRMS and dy-
namically regulated by disease-modifying treatment.
Plasma CCN3 levels were significantly higher in patients
on interferon-β treatment versus natalizumab. This is in-
triguing as both therapeutics decrease MS disease activ-
ity (CNS inflammatory lesions detected by MRI) and
relapse rates but by distinct mechanisms; IFN-β exerts
immunoregulatory effects on a range of immune cells
such as T cells and antigen-presenting cells whereas
natalizumab directly blocks T cell migration from the
vasculature into the CNS [56, 57]. In addition,
interferon-β treatment appeared to block the upregula-
tion of CCN3 in CD4+ T cells detected in all other MS
patient groups. Interferon-β can also act directly on adi-
pocytes suggesting that interferon-β may potentially
have independent effects on CCN3 expression by im-
mune cells and adipocytes.
A positive correlation was detected between plasma
and CSF CCN3 levels in MS which was absent in IIH
patients. This could be a result of passive protein level
changes associated by blood brain barrier breakdown in
MS [58], and/or a more actively induced change by infil-
tration of peripheral immune cells into the CNS com-
partment. Interestingly, the CCN3 isoforms identified in
blood differed from CSF. Whereas full-length CCN3 was
detected in both compartments, serum samples also
contained a shorter isoform around 25 kDa, similar in
size to the previously reported amino-truncated CCN3
species [3, 7, 8, 26, 36, 43, 59]. This may be due to dif-
ferentially regulated gene expression, post-translational
mechanisms or even different degradative processes in
these compartments [8]. Truncated isoforms of CCN3
are suggested to be developmentally regulated and have
previously been detected in brain tissue [26, 60].
In the CNS, we detected CCN3 expression in neurons,
blood vessels, astrocytes and choroid epithelia, demon-
strating that CCN3 can be produced by a range of neural
cell types. This is similar to reports of CCN3 expression
in mouse, though detection of CCN3 in blood vessels
and choroid epithelia has not been described in the mur-
ine CNS. CCN3 was upregulated upon toxin-induced
demyelination and specifically expressed in GFAP+ cells
and oligodendroglia within remyelinating lesions, al-
though it was not essential for efficient remyelination to
take place [32]. This would suggest that Treg-derived
CCN3 is not the principal cellular source of CCN3 in
the CNS particularly given the low density of Treg in the
CNS compared to neural cell types. Importantly, overall
CCN3 expression was similar in demyelinated, remyeli-
nated and normal-appearing tissue in the grey and white
matter of MS brain tissue. This suggests that a deficit of
CCN3 production is unlikely to be a factor limiting mye-
lin repair in MS lesions. The diverse neural sources of
CCN3 also suggest that CCN3 likely exerts a range of
biological functions beyond oligodendrocyte differenti-
ation, and indeed, expression in normal CNS tissue sug-
gests that CCN3 may fulfil key roles in CNS
homeostasis.
Though our previous work showed that Treg-derived
CCN3 was a positive mediator of oligodendrocyte differ-
entiation in vitro and ex vivo, comprehensive follow-up
was required to validate whether CCN3 would be an ap-
propriate target for remyelinating therapy. Our analysis
within the CNS, CSF or plasma suggests there is no sys-
temic deficiency of CCN3 to be targeted in MS. Recent
work from our group demonstrated that murine remye-
lination is still efficient in the absence of CCN3 [32].
This does not exclude the possibilities that binding part-
ners and signalling mediators of CCN3 could still con-
tribute to myelin repair. Functional mechanisms of
CCN3 in the CNS are still unknown and require further
study. Nonetheless, this work has highlighted dynamic
regulation of this multifaceted matricellular protein and
adipokine in MS that will be informative for future stud-
ies. Given the known roles and effects of CCN3 in
haematopoiesis and as an adipokine modulator of im-
mune function, it remains relevant to understand its ex-
pression profile particularly considering the pathogenic
role of both obesity and the adaptive immune system in
multiple sclerosis. The robust expression of CCN3 in
CNS and CSF also points to functions that have yet to
be uncovered. Our study provides a comprehensive
characterisation of CCN3 in the periphery and CNS.
This revealed dynamic profiles of CCN3 in MS disease
phase and treatment, and pointed to differential regula-
tion as an adipokine in patients with high BMI. How-
ever, the overarching finding of comparable systemic
levels of CCN3 in samples from healthy controls and
people with MS does not provide rationale to broadly
supplement CCN3 therapeutically in MS.
Conclusions
We analysed CCN3 in distinct cohorts to establish
physiological ranges and determine whether CCN3 is al-
tered by disease state in peripheral and in CNS compart-
ments. Ultimately, the robust expression of CCN3 in the
periphery and CNS of individuals with MS shows that
there is not an obvious CCN3 deficiency in MS that
should be directly targeted therapeutically, but its altered
profile of expression potentially points to additional cel-
lular players, functions and regulatory mechanisms.
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Whether therapeutic potential remains in the functional
realm of CCN3 biology will require future studies of hu-
man CCN3 in neural functional studies. Crucially, the
studies described here that provide a comprehensive
characterisation and comparative analysis of CCN3 in
MS and in different anatomical compartments will
underpin such future research efforts in this area.
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